TD Cowen Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

Analysts at TD Cowen started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report issued on Friday, MarketBeat.com reports. The firm set a “buy” rating on the stock.

Several other analysts have also recently weighed in on DNTH. Oppenheimer boosted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Trading Up 3.3 %

Shares of NASDAQ DNTH opened at $23.80 on Friday. Dianthus Therapeutics has a 1-year low of $7.75 and a 1-year high of $33.77. The company has a 50-day moving average of $25.69 and a two-hundred day moving average of $26.61. The company has a market cap of $704.48 million, a PE ratio of -9.52 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, equities research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC grew its stake in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the period. SG Americas Securities LLC bought a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at about $112,000. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $236,000. Fred Alger Management LLC increased its stake in Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth approximately $265,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.